What we are studying
The purpose of this study is to test the safety of the study drug, dabigatran etexilate, in children. You are being asked to take part in this study because you were previously treated for VTE with blood thinning drugs (for at least 3 months) or you have completed the clinical study 1160.106 (The DIVERSITY Study) treatment. In addition, you still have a risk factor for VTE and require further treatment with blood thinning drugs for secondary prevention of VTE. Because this is a research study, dabigatran will be given to you only during this study and not after the study is over.
$100.00 each for Visits 1 through Visit 12. The total amount of payment received for completing this study is $1100, as well as $100.00 for each additional (unscheduled) visit.